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Introduction
Multiple myeloma (MM) is still an incurable malignancy due to the development of drug resistant phenotype after prolonged therapy 1 2 . Several studies using various cancer models, including MM has provided evidence of therapeutic potential for vascular disrupting agents (VDAs) 3 4 5 VDAs disrupt functional tumor vasculature, reducing tumor blood flow and thereby causing tumor collapse with subsequent anoxia and tumor regression. 6 The importance of the vascular network as a therapeutic target to inhibit tumor growth 7 8 9 10 has led to the development of novel VDA; that act in a ligand-directed manner and prevent tubulin polymerization (e.g. plinabulin, fosbretabulin, ABT=751), which clearly differentiates them from the microtubulestabilizing agents (e.g., taxanes and epothilones). In addition, a phase-1 study of plinabulin as a single agent in patients with advanced malignancies (lung, prostrate and colon cancer) showed a favorable pharmacokinetic, pharmacodynamic and safety profile; and a Phase-2 study combining plinabulin with docetaxel in non-small cell lung cancer patients showed encouraging safety, pharmacokinetic, and efficacy data.
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In the present study, we show that the novel VDA plinabulin induces cell death in MM cells, without affecting 
Small interfering RNA (siRNA) Transfection
The JNK siRNA knockdown was performed using signal silence SAPK/JNK siRNA kit (cell Signaling, Beverly, MA).
Transfection was performed using cell line Nucleofactor Kit V solution (Amaxa Biosystems/Lonza), as per the manufacturer's instructions. In brief, MM.1S cells were transfected with JNK-I or JNK-II siRNA (Cell Signaling) and then separated them into two groups. The first groups of cells were cultured for 72h; protein lysates were then analyzed for the expression of JNK-I or JNK-II by immunoblotting using anti-JNK Ab. In the second group MM.1S cells were transfected with JNK siRNA; after 24h incubation, plinabulin (8nM) was added for an additional 48h, followed by analysis of viability using MTT assay.
Immunofluroscence assay Cells were grown in four well chambers slides (BD Falcon, Bedford, MA) and treated with plinabulin (8nM) for 24h. Cells were then washed twice in cell proliferation was then analyzed by thymidine incorporation assay. Results (Fig 4D) show that plinabulin induces MM cell death even in the presence of IL-6.
Plinabulin-induced apoptosis is associated with activation of caspases MM.1S, MM.1R, and RPMI-8226 cells
were treated with plinabulin (8nM, 48h), and protein lysates were subjected to immunoblot analysis. Plinabulin triggers PARP cleavage in all the three MM cells (Fig 5A) .
Furthermore, plinabulin induces activation of caspase-3, caspase-8 and caspase-9 (Fig 5A) . These findings indicate involvement of both intrinsic (caspase-8 mediated) and extrinsic (caspase-9 mediated) apoptotic signaling during plinabulin-induced MM cell death.
Plinabulin induced apoptosis in MM cells requires JNK
Cell death or apoptosis induced by plinabulin can also be for 30min), followed by plinabulin treatment (10nM, 48h) and analysis of cell death using trypan blue cell viability assay. Plinabulin-induced cell death was significantly blocked (80-85%) in the presence of JNK inhibitor ( Fig 5C) .
We further confirmed the involvement of JNK by using siRNA strategy. Blockade of JNK-I or JNK-II using siRNA significantly abrogated plinabulin-induced apoptosis (Fig 5D and 5E). Together these data confirm an obligatory role of JNK during plinabulin-induced MM cell death. (Fig 6C, lower panel (Fig 7B) . Importantly, increased survival was noted in mice receiving plinabulin vs. vehicle alone (P =0.0041; median survival in control was 15 days vs. 35 days in the plinabulin treatment group (Fig   For personal 
7C).
We next examined tumors from plinabulin-treated vs. control mice, and performed immunostaining for cleaved caspase-3, and vasculature related marker such as Factor VIII. As shown in Fig 7D, increase in cleaved caspase-3, was observed in tumor sections from plinabulin-treated group vs. controls (lower panel, Fig 7D) . Moreover, anti-vascular activity of plinabulin was evidenced by a significant reduction in Factor VIII expression (Fig 7D, upper panel) .
These results demonstrate that in vivo anti-MM activity of plinabulin is associated with disruption of tumor vasculature and pro-apoptotic activity.
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